The 'Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan' (OPTIMAAL), a randomized controlled trial involving 5477 patients compared captopril with losartan in high-risk post-MI patients and a non-significant higher mortality rate was observed in the group administered ARBs leading to the conclusion that this drug is not suitable for use in this patient population [34]. This evidence concerns the gene AGT and myocardial infarction.